No Data
Minsheng Securities: The results of medical insurance negotiations are now available, key products successfully included in the medical insurance catalog.
With the support of policies such as health insurance, the level of new drug research and development in China is continuously improving, the industrial scale is constantly expanding, and the number of new drugs under development in the country has jumped to the second place globally, accelerating the transition to high-quality innovation.
Zejing Pharmaceutical (688266.SH): Recombinant human thrombin included in the National Medical Insurance Pharmaceutical Directory for 2024.
On November 28th, Ge Longhui reported that Zejing Pharmaceutical (688266.SH) announced that the National Healthcare Security Administration, Ministry of Human Resources and Social Security released the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024)" (referred to as the "National Medical Insurance Drug List"), Suzhou Zejing Biopharmaceutical Co., Ltd.'s independently developed recombinant human coagulation factor has been included in the National Medical Insurance Drug List through national medical insurance negotiations. The 2024 National Medical Insurance Drug List will take effect on January 1, 2025.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Shares Could Be 49% Below Their Intrinsic Value Estimate
Zejing Pharmaceutical Report for the Third Quarter of 2024
Health Check: How Prudently Does Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) Use Debt?
Zelgen Biopharma Presents Phase 1/2 Data for Antitumor Drug at China Oncology Meet
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Popularity With Investors Under Threat As Stock Sinks 29%
